ATE65185T1 - Thrombolytische zusammensetzung und verfahren zu deren herstellung. - Google Patents

Thrombolytische zusammensetzung und verfahren zu deren herstellung.

Info

Publication number
ATE65185T1
ATE65185T1 AT86113507T AT86113507T ATE65185T1 AT E65185 T1 ATE65185 T1 AT E65185T1 AT 86113507 T AT86113507 T AT 86113507T AT 86113507 T AT86113507 T AT 86113507T AT E65185 T1 ATE65185 T1 AT E65185T1
Authority
AT
Austria
Prior art keywords
production
thrombolytic composition
plasminogen activator
tissue plasminogen
thrombolytic
Prior art date
Application number
AT86113507T
Other languages
English (en)
Inventor
Michio Ichimura
Hidemi Ohta
Kiyoshi Sakai
Yasuyuki Kunihiro
Takehisa Nakashiro
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16738163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE65185(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Application granted granted Critical
Publication of ATE65185T1 publication Critical patent/ATE65185T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT86113507T 1985-10-02 1986-10-01 Thrombolytische zusammensetzung und verfahren zu deren herstellung. ATE65185T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP60219606A JPH0672105B2 (ja) 1985-10-02 1985-10-02 血栓溶解剤及びその製法
EP86113507A EP0217379B1 (de) 1985-10-02 1986-10-01 Thrombolytische Zusammensetzung und Verfahren zu deren Herstellung

Publications (1)

Publication Number Publication Date
ATE65185T1 true ATE65185T1 (de) 1991-08-15

Family

ID=16738163

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86113507T ATE65185T1 (de) 1985-10-02 1986-10-01 Thrombolytische zusammensetzung und verfahren zu deren herstellung.

Country Status (5)

Country Link
EP (1) EP0217379B1 (de)
JP (1) JPH0672105B2 (de)
AT (1) ATE65185T1 (de)
CA (1) CA1340270C (de)
DE (2) DE217379T1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT391812B (de) * 1985-05-28 1990-12-10 Wellcome Found Verfahren zur herstellung einer parenteralen t-pa-loesung
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPS62120321A (ja) * 1985-11-20 1987-06-01 Eisai Co Ltd ｔＰＡ含有医薬組成物
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US4857320A (en) * 1987-02-19 1989-08-15 Monsanto Company Method of enhancing the solubility of tissue plasminogen activator
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
DE3832898A1 (de) * 1988-09-28 1990-04-12 Boehringer Mannheim Gmbh Praeparat von in prokaryonten exprimiertem plasminogenaktivator
AU4803890A (en) * 1988-12-15 1990-07-10 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
CA2156255C (en) * 1993-12-17 2008-02-05 Yasuyuki Kunihiro Soluble thrombomodulin-containing composition
FR2729972B1 (fr) * 1995-01-31 1997-04-18 Sanofi Sa Procede d'extraction de proteines periplasmiques de microorganismes procaryotes en presence d'arginine
US6139838A (en) * 1996-09-06 2000-10-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Tissue plasminogen activator medicinal composition
DE69814133T2 (de) * 1997-11-07 2004-04-01 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzung um die löslichkeit von igf-i zu erhöhen
US6767892B1 (en) 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
WO2000056328A1 (en) 1999-03-19 2000-09-28 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
JP4800739B2 (ja) * 2005-10-20 2011-10-26 デンカ生研株式会社 アッセイ用媒体及びアッセイ方法
PT3233111T (pt) 2014-12-19 2024-10-10 Kedrion Biopharma Inc Composição farmacêutica que compreende éniplasminogénio e seus usos
EP4125851B1 (de) * 2020-10-27 2025-06-18 Gosbert Weth Antivirale thrombosehemmende zusammensetzung zur verwendung bei der behandlung von covid-19 enthaltend arginin und thiocyanat

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK98833C (da) * 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
DE3203775A1 (de) * 1982-02-04 1983-08-11 Behringwerke Ag, 3550 Marburg Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
JPS6051119A (ja) * 1983-08-30 1985-03-22 Green Cross Corp:The ウロキナ−ゼ乾燥製剤
JPS60184026A (ja) * 1984-03-01 1985-09-19 Asahi Chem Ind Co Ltd 組織プラスミノ−ゲン・アクチベ−タ−の溶解補助方法
JPS60181028A (ja) * 1984-02-29 1985-09-14 Asahi Chem Ind Co Ltd 組織プラスミノ−ゲン・アクチベ−タ−の溶解補助法
JPS61124383A (ja) * 1984-11-16 1986-06-12 Unitika Ltd 固定化線維素溶解活性酵素の安定化法
CA1267602A (en) * 1985-09-10 1990-04-10 Fumio Kakimoto Composition containing tissue plasminogen activator
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
JP3035023B2 (ja) * 1991-09-13 2000-04-17 住友ベークライト株式会社 密封容器

Also Published As

Publication number Publication date
JPH0672105B2 (ja) 1994-09-14
CA1340270C (en) 1998-12-15
DE3680271D1 (de) 1991-08-22
EP0217379A2 (de) 1987-04-08
EP0217379B1 (de) 1991-07-17
DE217379T1 (de) 1989-01-26
EP0217379A3 (en) 1988-08-31
JPS6281326A (ja) 1987-04-14

Similar Documents

Publication Publication Date Title
ATE65185T1 (de) Thrombolytische zusammensetzung und verfahren zu deren herstellung.
MX9203338A (es) Nuevos derivados del oxico a_nor-esteroide-3-carboxilico.
DE3584902D1 (de) Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
ATE156355T1 (de) Stabile zusammensetzungen von askorbinsäure
DE69019084D1 (de) Methoden zur Verhinderung von Schimmel.
DE59008910D1 (de) Stabile injizierbare lösungen von faktor viii.
FI883838A7 (fi) Karbosyklisten happojen ja syklisten alkoholien sekä amiinien estereitä ja amideja.
DE69224124D1 (de) Verfahren zur Herstellung von Dihomo-Gamma-Linolensäure und das in dieser enthaltende Lipid
IL79114A0 (en) Method and composition for making liposomes
DE3881364D1 (de) Verfahren zur herstellung und zusammensetzungen von kollagen-derivaten.
DE69320928D1 (de) Verfahren zur Herstellung von Stärkeestern mit einem Mittelsubstitutionsgrad in wässriger Lösung
DE3688001D1 (de) Fruchtbarkeitsmittel enthaltend extrakte von coix lacryma-jobi oder ferulylstanolderivate und/oder fettsaeure-phytosterolester.
DE3869230D1 (de) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin.
ATE87657T1 (de) Enzymatisches verfahren.
ATE83652T1 (de) Verfahren zur herstellung von brausemischungen.
ATE113939T1 (de) Verfahren zur herstellung von cephalosporin und zwischenverbindungen.
DE3854266D1 (de) Verfahren zur Modifizierung eines Molekularsiebes.
DE69016087D1 (de) Stabile Lösungen von Rebeccamycinderivaten sowie deren Herstellung.
DK0610697T3 (da) Imidazolyl-substituerede phenyleddikesyreprolinamider.
DE3876361D1 (de) Herstellungsverfahren von carbonsaeureestern.
DE68921051D1 (de) Pyridin-3-percarboxylsäure monopersulfat.
DE69305250D1 (de) Herstellung von Alkandicarbonsäurederivaten
KR890701732A (ko) 개량형 조직 플라스미노겐 활성화 인자
ATE42087T1 (de) Verfahren zur herstellung von dichtem wasserfreiem natriumcarbonat und nach diesem verfahren hergestelltes dichtes wasserfreies natriumcarbonat.
DE3789523D1 (de) Verfahren zur Stabilisierung des Lactoperoxidase-Enzyms in Produkten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time